Hayat, Sikander
Kramann, Rafael http://orcid.org/0000-0003-4048-6351
Article History
First Online: 17 November 2022
Competing interests
: S.H. has funding from Novo Nordisk. R.K. has grants from Travere Therapeutics, Galapagos, Chugai and Novo Nordisk, and is a consultant or received honoraria from Bayer, Pfizer, Novo Nordisk, Lilly-Pharma and Gruenenthal.